Free Trial

Mersana Therapeutics (MRSN) Competitors

Mersana Therapeutics logo
$9.88 -0.65 (-6.17%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$9.95 +0.07 (+0.71%)
As of 10/17/2025 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MRSN vs. ACTU, CCCC, PYXS, CTOR, THTX, ACOG, NVCT, NKTX, MOLN, and GLSI

Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Actuate Therapeutics (ACTU), C4 Therapeutics (CCCC), Pyxis Oncology (PYXS), Citius Oncology (CTOR), Theratechnologies (THTX), Alpha Cognition (ACOG), Nuvectis Pharma (NVCT), Nkarta (NKTX), Molecular Partners (MOLN), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry.

Mersana Therapeutics vs. Its Competitors

Actuate Therapeutics (NASDAQ:ACTU) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Actuate Therapeutics currently has a consensus price target of $20.33, indicating a potential upside of 171.84%. Mersana Therapeutics has a consensus price target of $56.60, indicating a potential upside of 472.87%. Given Mersana Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mersana Therapeutics is more favorable than Actuate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actuate Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Mersana Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, Actuate Therapeutics' average media sentiment score of 0.00 equaled Mersana Therapeutics'average media sentiment score.

Company Overall Sentiment
Actuate Therapeutics Neutral
Mersana Therapeutics Neutral

Actuate Therapeutics has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Actuate Therapeutics has higher earnings, but lower revenue than Mersana Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actuate TherapeuticsN/AN/A-$27.28MN/AN/A
Mersana Therapeutics$34.77M1.42-$69.19M-$14.62-0.68

Actuate Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%.

Company Net Margins Return on Equity Return on Assets
Actuate TherapeuticsN/A N/A -281.83%
Mersana Therapeutics -212.94%N/A -54.85%

93.9% of Mersana Therapeutics shares are owned by institutional investors. 69.3% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 13.0% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Mersana Therapeutics beats Actuate Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Mersana Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRSN vs. The Competition

MetricMersana TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$49.31M$3.44B$6.19B$10.56B
Dividend YieldN/A2.27%5.70%4.81%
P/E Ratio-0.6823.0185.5427.12
Price / Sales1.42500.54613.32133.32
Price / CashN/A46.9237.1060.81
Price / Book-5.1510.4112.236.52
Net Income-$69.19M-$52.77M$3.33B$276.93M
7 Day Performance6.93%2.31%1.17%1.93%
1 Month Performance36.28%12.59%6.85%2.19%
1 Year Performance-81.18%11.18%58.93%34.62%

Mersana Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRSN
Mersana Therapeutics
4.1034 of 5 stars
$9.88
-6.2%
$56.60
+472.9%
-81.2%$49.31M$34.77M-0.68150
ACTU
Actuate Therapeutics
1.4469 of 5 stars
$7.02
+0.6%
$20.33
+189.6%
+3.0%$162.24MN/A0.0010
CCCC
C4 Therapeutics
3.5467 of 5 stars
$2.28
+0.4%
$8.50
+272.8%
-62.7%$161.56M$35.58M-1.44150News Coverage
PYXS
Pyxis Oncology
2.8256 of 5 stars
$2.47
-3.9%
$7.75
+213.8%
-10.4%$159.39M$16.15M-1.5460Gap Up
CTOR
Citius Oncology
2.0474 of 5 stars
$1.87
-1.1%
$6.00
+220.9%
+37.1%$157.84MN/A0.00N/ANews Coverage
Gap Up
THTX
Theratechnologies
N/A$3.42
+0.9%
N/A+157.1%$157.21M$84.38M-17.99140High Trading Volume
ACOG
Alpha Cognition
2.319 of 5 stars
$7.40
-1.1%
$20.00
+170.3%
N/A$156.35MN/A-4.63N/AAnalyst Downgrade
Short Interest ↑
NVCT
Nuvectis Pharma
2.5841 of 5 stars
$6.05
+0.7%
$15.33
+153.4%
-18.8%$152.87MN/A-5.178News Coverage
NKTX
Nkarta
2.4429 of 5 stars
$2.15
+0.9%
$13.60
+532.6%
-46.0%$151.28MN/A-1.45140High Trading Volume
MOLN
Molecular Partners
1.4854 of 5 stars
$3.72
+0.3%
$8.00
+115.0%
-22.1%$149.79M$5.65M-1.79180Analyst Forecast
Gap Down
GLSI
Greenwich LifeSciences
1.2141 of 5 stars
$11.28
+3.4%
$42.00
+272.3%
-29.9%$148.71MN/A-8.293Analyst Forecast

Related Companies and Tools


This page (NASDAQ:MRSN) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners